Adults 21 to 64, any sex, with Asthma or Obesity. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Beliefs About Illness Perception Questionnaire (BIPQ)Primary· At 30 days Post-pilot follow-up visit, up to 2 months
BIPQ includes 5 cognitive domains (Identity, Cause, Timeline, Consequences, and Cure-Control) designed to rapidly assess the cognitive and emotional representations of illness. Each item in each domain is scored on a 0 (none) to 10 (extreme). Full scale from 0-80, where higher score reflects a more threatening view of the illness.
Group
Value
95% CI
Asthma and Exercise Lifestyle Change
42.6
± 11.4
Asthma Education
36.2
± 8.2
Medication Adherence Rating Scale (MARS)Secondary· At 30 days Post-pilot follow-up visit, up to 2 months
MARS is a self-reported questionnaire with the total score range from 0-10 with a higher score indicating better adherence.
Group
Value
95% CI
Asthma and Exercise Lifestyle Change
4.7
± 0.5
Asthma Education
4.7
± 0.5
Physical Activity - Step Counts Per DaySecondary· Week 2, Week 4, and at 30 days Post-pilot follow-up visit
Physical activity monitoring using accelerometer and accompanying activity diary for self-report of wear. The accelerometer will measure step counts using previously determined cut-points. Based on accepted methodology, 3 or more out of the 7 days with 10 or more hours of wear time will be considered a valid measure of usual activity.
Week 2
Group
Value
95% CI
Asthma and Exercise Lifestyle Change
12253.3
± 0
Asthma Education
2499.7
± 1514.9
Week 4
Group
Value
95% CI
Asthma and Exercise Lifestyle Change
13730.2
± 0
Asthma Education
2123.9
± 1751.0
at 30 days post pilot follow-up visit
Group
Value
95% CI
Asthma and Exercise Lifestyle Change
2667.9
± 375.4
Asthma Education
3715.1
± 3041.5
Time in Physical ActivitySecondary· Week 2, Week 4, and at 30 days Post-pilot follow-up visit
Physical activity monitoring using accelerometer and accompanying activity diary for self-report of wear. The accelerometer measured time spent in different intensities of activity using previously determined cut-points. Based on accepted methodology, 3 or more out of the 7 days with 10 or more hours of wear time was considered a valid measure of usual activity.
Week 2
Group
Value
95% CI
Asthma and Exercise Lifestyle Change
74.5
± 0
Asthma Education
8.6
± 7.0
Week 4
Group
Value
95% CI
Asthma and Exercise Lifestyle Change
91.5
± 0
Asthma Education
10.3
± 8.3
at 30 days post pilot follow-up visit
Group
Value
95% CI
Asthma and Exercise Lifestyle Change
9.9
± 6.8
Asthma Education
7.8
± 9.2
Asthma Control Questionnaire (ACQ)Secondary· at 30 days Post-pilot follow-up visit, up to 2 months
Asthma Control Questionnaire (ACQ) - self-reported asthma control validated survey, with a total score range from 0-6, with a higher score indicating severely uncontrolled asthma, used to assess current asthma control at 30 days post-pilot follow up visit.
Group
Value
95% CI
Asthma and Exercise Lifestyle Change
1.6
± 1.0
Asthma Education
1.3
± 0.9
Asthma Quality of Life Questionnaire (AQLQ)Secondary· at 30 days post-pilot follow-up visit, up to 2 months
Asthma Quality of Life Questionnaire (AQLQ) - self-reported asthma-related quality of life validated survey used to assess asthma-related quality of life at 30 days post-pilot follow-up visit. Total Score from 1-7, with higher score indicating better quality of life.
Group
Value
95% CI
Asthma and Exercise Lifestyle Change
4.9
± 0.8
Asthma Education
5.0
± 0.6
Beliefs About Medications Questionnaire (BMQ) - Necessity and Concerns SubscaleSecondary· at 30 days post pilot follow-up visit, up to 2 months
Beliefs about Medications Questionnaire (BMQ) - Necessity and Concerns
The BMQ comprises two separate two five-item sub-scales (Necessity and Concerns) and assesses respondents' beliefs about prescribed medicines that they are currently using for specific conditions, for e.g. asthma.
It assesses patients' beliefs about the necessity of prescribed medication for controlling their disease and their concerns about potential adverse consequences of taking it. Respondents indicate their degree of agreement with each statement on a five-point Likert scale, ranging from 1 - strongly disagree to 5 -
Necessity Subscale
Group
Value
95% CI
Asthma and Exercise Lifestyle Change
15
± 3.6
Asthma Education
16.4
± 5
Concerns Subscale
Group
Value
95% CI
Asthma and Exercise Lifestyle Change
8.4
± 1
Asthma Education
8.4
± 2.7
Sponsor's own description
Develop and pilot test four theory-based educational modules that integrate counseling for asthma and obesity to promote greater physical activity among people with asthma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t
· Phase 2
· recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being
· NA
· recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice
· recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ
· Phase 1
· recruiting
Other Icahn School of Medicine at Mount Sinai trials
Trials by the same sponsor.
NCT07094308 — The LIFT-ECHO Last Mile Project
· NA
· not yet recruiting
NCT07291427 — Chronic Subdural Hematoma Embolization With Detachable Coils
· not yet recruiting
NCT07194187 — High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction
· NA
· not yet recruiting
NCT07260916 — Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation
· NA
· not yet recruiting
NCT07487948 — Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and
· Phase 2
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai
Last refreshed: 14 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04113746.